Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it will present new pre-clinical data from its ALN-AT3, ALN-CC5, and ALN-TMP programs at the 55th Annual Meeting of the American Society of Hematology (ASH) being held December 7 – 10, 2013 in New Orleans, Louisiana.
Help employers find you! Check out all the jobs and post your resume.
